ACELRX PHARMACEUT. DL-01 (R5XA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.44 Million ≈ $-2.85 Million USD) by net assets (€17.04 Million ≈ $19.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ACELRX PHARMACEUT. DL-01 (R5XA) total market value for the company's overall valuation and market capitalisation.
ACELRX PHARMACEUT. DL-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ACELRX PHARMACEUT. DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their cash flow conversion efficiency. Explore ACELRX PHARMACEUT. DL-01 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IFirma SA
WAR:IFI
|
0.126x |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
-0.078x |
|
Pioneer Power Solutions Inc.
NASDAQ:PPSI
|
-0.033x |
|
Thai Textile Industry Public Company Limited
BK:TTI
|
0.013x |
|
BioSmart Co.Ltd
KQ:038460
|
0.042x |
|
Sealink International Bhd
KLSE:5145
|
-0.080x |
|
IRIS Corporation Bhd
KLSE:0010
|
-0.003x |
|
KRONA PUBLIC REAL ESTATE
F:927
|
-0.037x |
Annual Cash Flow Conversion Efficiency for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. View ACELRX PHARMACEUT. DL-01 share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €17.04 Million ≈ $19.92 Million |
€-11.36 Million ≈ $-13.29 Million |
-0.667x | +57.92% |
| 2024-12-31 | €8.00 Million ≈ $9.35 Million |
€-12.68 Million ≈ $-14.83 Million |
-1.585x | -27.82% |
| 2023-12-31 | €14.11 Million ≈ $16.49 Million |
€-17.49 Million ≈ $-20.45 Million |
-1.240x | +4.51% |
| 2022-12-31 | €21.81 Million ≈ $25.50 Million |
€-28.33 Million ≈ $-33.12 Million |
-1.299x | -255.38% |
| 2021-12-31 | €-35.89 Million ≈ $-41.96 Million |
€-30.00 Million ≈ $-35.08 Million |
0.836x | -- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more